Investment Analysts’ Recent Ratings Updates for Climb Bio (CLYM)

Climb Bio (NASDAQ: CLYM) has recently received a number of price target changes and ratings updates:

• 11/7/2026 – Climb Bio was upgraded by Wall Street Zen from “sell” to “hold”.
• 11/5/2026 – Climb Bio had its price target raised by Wedbush from $25.00 to $27.00. They now have an “outperform” rating on the stock.
• 11/5/2026 – Climb Bio had its “strong-buy” rating reaffirmed by Raymond James Financial.
• 10/27/2026 – Climb Bio had its “overweight” rating reaffirmed by Piper Sandler.
• 10/27/2026 – Climb Bio had its “buy” rating reaffirmed by BTIG Research. They now have a $32.00 price target on the stock.
• 10/26/2026 – Climb Bio had its “buy” rating reaffirmed by Guggenheim.
• 10/20/2026 – Climb Bio is now covered by Deutsche Bank Aktiengesellschaft. They set a “buy” rating and a $28.00 price target on the stock.
• 10/15/2026 – Climb Bio had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/12/2026 – Climb Bio had its “buy” rating reaffirmed by HC Wainwright.
• 10/5/2026 – Climb Bio had its “strong-buy” rating reaffirmed by Raymond James Financial. They now have a $34.00 price target on the stock.
• 10/3/2026 – Climb Bio was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/16/2026 – Climb Bio was upgraded by Mizuho to “strong-buy”.

Climb Bio Price Performance

Climb Bio stock traded up $1.06 during mid-day trading on Monday, reaching $11.36. 447,449 shares of the stock traded hands, compared to its average volume of 1,061,546. The stock has a market capitalization of $655.52 million, a PE ratio of -13.85 and a beta of 0.01. Climb Bio, Inc. has a 12-month low of $1.63 and a 12-month high of $18.33. The business’s 50-day moving average is $11.91 and its 200-day moving average is $10.47.

Climb Bio (NASDAQ:CLYM) last announced its earnings results on Thursday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.02. Equities analysts anticipate that Climb Bio, Inc. will post -0.79 EPS for the current fiscal year.

Insider Buying and Selling at Climb Bio

In other news, Director Stephen Thomas sold 100,000 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $13.67, for a total value of $1,367,000.00. Following the transaction, the director owned 467,969 shares in the company, valued at $6,397,136.23. This represents a 17.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.60% of the stock is owned by company insiders.

Climb Bio, Inc (NASDAQ: CLYM) is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. The company is working to create medicines that target B cells, which play a central role in the immune responses associated with many autoimmune disorders.

Climb Bio’s lead investigational product, CLYM116, is a fully human anti-CD19 monoclonal antibody designed to selectively deplete B cells. The therapy is being evaluated in clinical development for autoimmune conditions, including primary membranous nephropathy, a kidney disorder in which abnormal immune activity can damage the kidneys.

As a development-stage biotechnology company, Climb Bio’s activities are centered on research, clinical trials and the potential commercialization of its pipeline rather than on marketed products.